| abstract |
Disclosed is the use of a pharmaceutical composition comprising less than 0.5 mg of a 2-amino-2-[2-(4-C2-20 alkylphenyl)ethyl]propane-1,3-diol compound for the treatment, prevention or delay of progression of multiple sclerosis in a patient, wherein the composition is adapted for oral administration and wherein the patient is a paediatric patient such as an infant, child or adolescent. 2-amino-2-[2-(4-C2-20 alkylphenyl)ethyl]propane-1,3-diol compounds include FTY720 (fingolimod) and FTY720 phosphate. |